Via Pharmaceuticals Inc · OTC:VIAP
Via Pharmaceuticals — Corautus Genetics — BIO CEO & Investor Conference 2004
29 slides from Via Pharmaceuticals's conference presentation, Feb 24, 2004
Slide 1: The New Era of Biologic Revascularization for Refractory Myocardial Ischemia
The New Era of Biologic Revascularization for Refractory Myocardial Ischemia Richard E. Otto President and CEO February 24, 2004
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains “forward-looking statements” within the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 with respect to Corautus Genetics’ financial condition, intellectual property, results of operations and businesses, research
Slide 3: Corautus Genetics: At a Glance
Corautus Genetics: At a Glance The Science: Genomic Therapeutics The Target: Vascular Endothelial Growth Factor-2 (VEGF-2) Initial Focus: Refractory Myocardial Ischemia (Severe CAD) Estimated Market: $1 billion in the US annually Clinical Status: Phase I/IIa Completed; Phase Ilb early 2004 Strategic
Slide 4: Jeffery M. Isner, M.D. & Vascular Genetics Inc.
Jeffery M. Isner, M.D. & Vascular Genetics Inc. ‘No discussion on therapeutic angiogenesis would be appropriate without honoring the person who was clearly the leader in the field. Dr. Jeffery M. IsnerJeff was the consummate Clinician/Scientist and without question the pioneer in this area.’ Cardiol
Slide 5: The Vision – Biologic Revascularization
The Vision – Biologic Revascularization Conventional vs. Regenerative Pharmacologic Biologic (Genetic) Treats Symptom Treats Cause Underlying condition unaltered Underlying condition altered Biologic revascularization may offer superior outcomes in the treatment of refractory angina due to remodelin
Slide 6: The Opportunity
The Opportunity oO CORAUTUS GENETICS
Slide 7: Coronary Artery Disease Market Size
Coronary Artery Disease Market Size “The New Era” ———————————— Conventional ———————————— Regenerative Opportunity MEDICAL THERAPY INTERVENTION SURGERY REFRACTORY Nitroglycerin, Beta MYOCARDIAL Blockers, Calcium PTCA / Stent CABG ISCHEMIA Antagonists, Statins $1 Billion (*) Corautus will deliver nake
Slide 8: Refractory Myocardial Ischemia
Refractory Myocardial Ischemia Class III-IV refractory angina Cardiac muscle demand for 02 is greater than supply Significant chest pain on minimal or no exertion No proven therapy for Class III-IV refractory angina Poor quality of life Significant demand for effective treatment
Slide 9: Clinical Results – Phase I and IIa
Clinical Results – Phase I and IIa Phase I – Mini Thoracotomy 30 Class III/IV angina patients injected directly into myocardium Positive clinical results – 74% patients reported a reduction in angina of greater than 2 classes – Episodes of angina fell from 31 to 9/week – Exercise time increased an a
Slide 10: SPECT Nuclear Results: VEGF-2
SPECT Nuclear Results: VEGF-2 Source: Articles published by investigators in Circulation, April 30, 2002
Slide 11: Phase I Clinical Results: CCS Class Angina
Phase I Clinical Results: CCS Class Angina Time after VEGF-2 Injection (Months) Source: Articles published by investigators in The American Journal of Cardiology, August 15, 2003
Slide 12: Phase IIb Trial
Phase Ilb Trial oO CORAUTUS GENETICS
Slide 13: Physician Advisors
Physician Advisors Douglas W. Losordo, M.D. – National Principal Investigator Involved in research with Dr. Isner for 14 years Chief, Cardiovascular Research St. Elizabeth’s Medical Center Associate Professor of Medicine Tufts University School of Medicine Editorial Board, Circulation Richard A. Sch
Slide 14: Phase IIb Clinical Trial Design
Phase Ilb Clinical Trial Design National multi-center, double-blind, dose ranging N = 404, four cohorts (0, 20?g, 200?g, 800?g) Class III and IV angina “no op” patients Boston Scientific StilettoTM Catheter Efficacy data measured at 3 months, safety data at 1 year 15 clinical sites in the United Sta
Slide 15: FDA Review Process of Combination Products
FDA Review Process of Combination Products Center for Biologics Evaluation and Research (“CBER”) Responsible for complete review of the entire submission Reviews submission and refers device questions/concerns to CDRH Reports all CBER and CDRH comments to Sponsor of IND Dialogue ongoing—additional g
Slide 16: Competitive Landscape
Competitive Landscape oO CORAUTUS GENETICS
Slide 17: Late-Stage Competitive Landscape
Late-Stage Competitive Landscape Berlex Fibroblast Growth Factor Viral Vector (Collateral Therapeutics) Class II-III angina Coronary artery injection Phase IIB/III Terminated Jan. 2004 due to lack of efficacy VEGF-121 Viral Vector GenVec Class II-IV angina Collaboration with Cordis Corporation Europ
Slide 18: Company Highlights
Company Highlights oO CORAUTUS GENETICS
Slide 19: Recent Accomplishments
Recent Accomplishments OBJECTIVE: RESULTS: Merger of Vascular Genetics / GenStar Therapeutics Recapitalized $18 million debt at 70% reduction Negotiated ownership of all clinical & regulatory data from previous CRO Restructured license agreement of VEGF-2 with Human Genome Sciences, Inc. Corporate R
Slide 20: Intellectual Property
Intellectual Property Boston Scientific Human Genome Corporation Sciences Inc. Corautus Genetics Inc. Caritas St. Elizabeth’s Vical Inc. Medical Center Corautus believes it has a fortress IP position in cardiovascular gene therapy and that no additional licenses are required for commercialization
Slide 21: Financing Activities
Financing Activities Boston Scientific Corporation—$25M potential investment July 2003 ?? 9M convertible preferred for 10% fully diluted equity ?? 1M sublicense fee ?? 15M convertible notes in three tranches based upon milestones •$ 2.5M accelerated draw in December 2003 Private Placements—$8.45M $2
Slide 22: Fully Diluted Ownership Summary – January 31, 2004
Fully Diluted Ownership Summary – January 31, 2004 Shares (thousands) % Human Genome Sciences Inc. 1,585 10 Boston Scientific Corporation 1,396 9 Baxter Healthcare Corporation 1,397 9 Ardsley Partners and affiliates 1,200 7 Caritas St. Elizabeth’s Medical Center 308 2 Vical Incorporated 241 1 Sub-To
Slide 23: Market Capitalization
Market Capitalization Market Capitalization 5X+ increase $15,000,000 3/31/03 $85,000,000 2/18/04
Slide 24: oO CORAUTUS
oO CORAUTUS GENETICS
Slide 25: Management Goals
Management Goals Commence and Manage Phase IIB clinical trial Initiate phase III-commercial product manufacturing Efficiently deploy capital by controlling costs Secure additional funding for 2005 and beyond Focus R&D efforts on later-stage opportunities Consider Investigational New Drug Application
Slide 26: Conclusion
Conclusion oO CORAUTUS GENETICS
Slide 27: Conclusion
Conclusion “Later-stage” therapeutic serving an unmet medical condition Support of key opinion leaders in cardiology $1 billion estimated US annual market opportunity for Refractory CAD Major collaboration agreement with Boston Scientific Corporation Fortress of intellectual property Recently streng
Slide 28: Conclusion
Conclusion 2003—Emerged as a Strong Survivor 2004—Significant Event-Driven Valuation Opportunities
Slide 29: Contact details
75 Fifth Street, NW Suite 313 Atlanta, GA 30308 404.526.6200 www.corautus.com Richard E. Otto Robert T. Atwood President and CEO Executive VP and CFO
Corautus Genetics — BIO CEO & Investor Conference 2004 on 6ix